Trump to press Putin to end 'bloodbath' in Ukraine
Russian President Vladimir Putin and U.S. President Donald Trump.
Mikhail Metzel | Evelyn Hockstein | Via Reuters
U.S. President Donald Trump will speak separately with Vladimir Putin and Volodymyr Zelenskyy on Monday in hopes of ending the 'bloodbath' in Ukraine, amid concerns over Washington's ongoing push to broker peace-making.
'HOPEFULLY IT WILL BE A PRODUCTIVE DAY, A CEASEFIRE WILL TAKE PLACE, AND THIS VERY VIOLENT WAR, A WAR THAT SHOULD HAVE NEVER HAPPENED, WILL END,' Trump wrote on his Truth social media platform Saturday in his customary all-capitalized comments.
The subject of the call will be trade and stopping the 'bloodbath' of Russian and Ukrainian deaths, he said.
His call with Putin will take place at 5 p.m. Moscow time (10:00 a.m. E.T.) and will take into account the outcome of negotiations carried out last week in Istanbul, Kremlin Spokesperson Dmitry Peskov said Monday, according to Google-translated comments carried by Russian state news agency Tass.
The U.S. mediation is set to happen after representatives from Russia and Ukraine held their first face-to-face talks since 2022 in Istanbul last week, as part of downgraded discussions that had originally been hoped to bring together Moscow and Kyiv's heads of state. Putin and Trump ultimately spurned the meeting, which culminated in an agreement to exchange prisoners of war, but failed to progress the peace process.
Talks to end the three-year war in Ukraine have languished in recent months, despite a U.S. drive to materialize Trump's pledge to achieve peace urgently. Threats from Trump that Washington could withdraw from the diplomatic process in the absence of an imminent resolution have raised concerns that the White House might diminish its critical military and humanitarian support for Ukraine.
Trump, whose revived dormant relations with the Kremlin after years of frigidity under his predecessor Joe Biden's administration, has recently turned tack on his reluctance to directly criticize Putin, increasingly levying the possibility of further sanctions on Moscow and backing a Ukraine and Europe-endorsed call for a 30-day ceasefire.
The contours of a temporary truce or permanent peace proposal have remained elusive, amid maximalist Russian demands and Zelenskyy's unwillingness to entertain potential territorial concessions.
'The U.S. has presented a strong peace plan and we welcome the Prisoner of War exchange agreement reached in Istanbul. Let's not miss this huge opportunity. The time for ending this war is now,' U.S. Secretary of State Marco Rubio said on social media Saturday, following a call with Russian Foreign Minister Sergey Lavrov.
'He explained to me that they are going to be preparing a document outlining their requirements for a ceasefire that will then lead to broader negotiations,' Rubio said in a later TV interview with CBS. 'Obviously, the Ukrainian side is going to be working on their own proposal. And hopefully that will be forthcoming soon.'
Yet the signs of Washington's dwindling patience with the stalled process linger.
'We don't want to be involved in this process of just endless talks. There has to be some progress, some movement forward,' Rubio stressed.
On Sunday, Zelenskyy also met with Rubio and U.S. Vice President JD Vance, decrying on social media the 'low level delegation of non-decision-makers' deployed by Russia to Istanbul last week, adding that he reaffirmed that 'Ukraine is ready to be engaged in real diplomacy and underscored the importance of a full and unconditional ceasefire as soon as possible.'
Sidelined throughout much of the recent peace brokering, European officials have raced to engage with the White House, with British, U.S., Italian, French and German leaders discussing Trump's upcoming engagement with Putin during a call on Sunday.
'Looking ahead to President Trump's call with President Putin tomorrow, the leaders discussed the need for an unconditional ceasefire and for President Putin to take peace talks seriously,' a British government readout said. 'They also discussed the use of sanctions if Russia failed to engage seriously in a ceasefire and peace talks.'
READ SOURCE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Aluminum can maker Ball Corp lifts annual profit forecast buoyed by strong global demand
(Reuters) -Ball Corp raised its annual profit forecast on Tuesday, after beating second-quarter results, fueled by resilient demand for its aluminum cans in key markets of North America and Europe, sending its shares up 2% in premarket trading. Ball witnessed a 4.1% rise in global aluminum packaging shipments during the quarter, up from a 2.6% rise in the prior three months. This was driven by demand from packaged food firms, as consumers opted for canned foods and beverages amid sticky inflation, prompting them to cook more at home. The company, serving clients like PepsiCo, Coca-Cola and Constellation Brands, increased beverage packaging sales in North and Central America to $1.61 billion, from $1.47 billion last year. The manufacturer of aluminum cups, bottles and aerosol cans now expects comparable 2025 earnings to grow between 12% and 15%, up from a prior range of 11% to 14% growth. However, tariffs on steel and aluminum have pushed up input costs for companies such as Ball. "We continue to view the direct impact from announced tariffs as manageable and are actively working with our customers to mitigate the effects of volatility in aluminum premium prices," the company said on Tuesday. Ball CEO Daniel Fisher said the company was tightly managing its costs as it expects potential geopolitical uncertainties and market volatility in the second half of the year. Excluding items, it earned a profit of 90 cents per share in the quarter, beating expectations of 87 cents per share, according to data compiled by LSEG. Its revenue jumped 7.8% to $3.34 billion, above estimates of $3.12 billion.
Yahoo
14 minutes ago
- Yahoo
New US-EU trade deal on tariffs ends pharma's geopolitical immunity
For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU. On 27 July, the US government announced a 15% tariff on branded pharmaceutical products imported from the EU. Despite the decrease from the original 30% tariff on pharmaceuticals earlier in the year, this disrupts a long-established practice of the exemption of medicines from tariffs due to their importance in public health. The 15% tariff is not expected to happen immediately as implementation will be dependent on a National Security investigation regarding pharmaceutical imports. This trade deal puts the pharmaceutical industry at risk of losing between $13bn and $19bn, with consequences that extend beyond short-term financials. It will force pharmaceutical companies to make a tradeoff between tightening their profit margins and increasing drug prices, with both paths posing a risk to patient access and payer relations. The imposition of tariffs threatens to elevate costs across the pharmaceutical value chain, and could lead to a substantial increase in drug development costs, manufacturing, and distribution, with global supply chains for active pharmaceutical ingredients (APIs), raw materials, and equipment directly exposed. This disruption could create uncertainty in launch planning, particularly for late-stage assets with EU-based manufacturing and production planned for US entry. Companies manufacturing pharmaceutical products in Europe will need to anticipate financial exposure when planning launches in the US due to the unfavourable gross-to-net dynamics, weakened pricing leverage with US payers, and slower commercial uptake as insurers reassess cost-effectiveness due to the tariffs. Research and development budgets are already under pressure, and may be further strained as pharmaceutical companies may have to divert budget to firefight the impact of the tariffs. This could hinder innovation and pipeline investment, reducing the much-needed pace of therapeutic innovation across the industry. Earlier in the year, the US administration did signal tariffs for pharmaceutical imports could become a real possibility; this was met with proactive US investment from leading pharmaceutical companies to onshore manufacturing in the US to reduce exposure. Most recently, in July 2025, Biogen announced a $2bn investment into North Carolina, strengthening its US manufacturing position. Other pharmaceutical companies such as Johnson & Johnson, AstraZeneca, and Eli Lilly have also increased their investment in US manufacturing, with investments of $55bn, $50bn, and $27bn, respectively. Ultimately, the recent US-EU trade deal has increased the level of uncertainty within the pharmaceutical industry, raising concerns about the potential of tariffs increasing past 15% in the future. A once-shielded sector is facing a geopolitical shift, leaving the pharmaceutical industry vulnerable to global volatility. "New US-EU trade deal on tariffs ends pharma's geopolitical immunity" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
14 minutes ago
- Yahoo
Tapestry sells footwear brand Stuart Weitzman to Caleres
US-based footwear company Caleres has completed the acquisition of luxury footwear brand Stuart Weitzman from global fashion house Tapestry for $120.2m. The total price includes $11.5m in cash received at close, bringing the net purchase price to $108.7m, subject to adjustments based on net working capital. The acquisition was initially announced in February 2025. Caleres is expected to reinforce its position in the women's fashion footwear sector through the acquisition, while Tapestry will concentrate its efforts on accelerating growth for its Coach and Kate Spade brands. Jonathan Lelonek, who joined Stuart Weitzman in 2012 and most recently served as senior vice-president of global wholesale, has been appointed as the brand's president. Lelonek's experience in the luxury and contemporary footwear sectors, including senior roles at Prada, Salvatore Ferragamo and Paul Frank, positions him well to steer Stuart Weitzman's future growth. Stuart Weitzman has reported 12-month sales of $220m and maintains a robust presence in North America, Europe and Asia, spanning wholesale and direct-to-consumer channels. Caleres aims to use its expertise in footwear to guide Stuart Weitzman back to profitability following a period of transition and integration for the remainder of the fiscal year 2025. Caleres president and CEO Jay Schmidt stated: 'Stuart Weitzman is one of the most iconic names in luxury footwear, and the brand's original designs have embodied elegance and modernity for decades. We are honoured to welcome Stuart Weitzman to Caleres as our newest lead brand and to congratulate Jonathan on his appointment as brand president. 'With the addition of Stuart Weitzman, our brand Pportfolio segment will represent nearly half of our total revenue going forward. As we integrate this iconic brand, we remain committed to preserving the artistry, quality and renowned fit at the brand's core.' The acquisition was financed through Caleres' revolving credit agreement. BofA Securities acted as financial advisor, and Bryan Cave Leighton Paisner provided legal counsel for Caleres in this transaction. "Tapestry sells footwear brand Stuart Weitzman to Caleres" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
